199 related articles for article (PubMed ID: 11440030)
41. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
Degirmenci B; Wilson D; Laymon CM; Becker C; Mason NS; Bencherif B; Agarwal A; Luketich J; Landreneau R; Avril N
Nucl Med Commun; 2008 Jul; 29(7):614-22. PubMed ID: 18528183
[TBL] [Abstract][Full Text] [Related]
42. The use of dual-phase 18F-FDG PET in characterizing thyroid incidentalomas.
Hsiao YC; Wu PS; Chiu NT; Yao WJ; Lee BF; Peng SL
Clin Radiol; 2011 Dec; 66(12):1197-202. PubMed ID: 21907336
[TBL] [Abstract][Full Text] [Related]
43. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
44. The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT.
Strobel K; Exner UE; Stumpe KD; Hany TF; Bode B; Mende K; Veit-Haibach P; von Schulthess GK; Hodler J
Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2000-8. PubMed ID: 18712385
[TBL] [Abstract][Full Text] [Related]
45. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
[TBL] [Abstract][Full Text] [Related]
46. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Tokunaga M; Koyama Y; Sato N; Endo K
Skeletal Radiol; 2003 Mar; 32(3):133-8. PubMed ID: 12605276
[TBL] [Abstract][Full Text] [Related]
47. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
[TBL] [Abstract][Full Text] [Related]
48. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer.
Lapela M; Eigtved A; Jyrkkiö S; Grénman R; Kurki T; Lindholm P; Nuutinen J; Sutinen E; Solin O; Bjornskov I; Bretlau P; Friberg L; Holm S; Jensen M; Sand Hansen H; Minn H
Eur J Cancer; 2000 May; 36(7):858-67. PubMed ID: 10785590
[TBL] [Abstract][Full Text] [Related]
49. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
50. FDG-PET and CT characterization of adrenal lesions in cancer patients.
Jana S; Zhang T; Milstein DM; Isasi CR; Blaufox MD
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):29-35. PubMed ID: 16193311
[TBL] [Abstract][Full Text] [Related]
51. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
52. 18FDG PET scanning of benign and malignant musculoskeletal lesions.
Feldman F; van Heertum R; Manos C
Skeletal Radiol; 2003 Apr; 32(4):201-8. PubMed ID: 12652335
[TBL] [Abstract][Full Text] [Related]
53. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
54. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
[TBL] [Abstract][Full Text] [Related]
55. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
Cho WI; Chang UK
J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
[TBL] [Abstract][Full Text] [Related]
56. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
Chae EY; Cha JH; Kim HH; Shin HJ; Kim HJ; Oh HY; Koh YH; Moon DH
Acta Radiol; 2012 Jun; 53(5):530-5. PubMed ID: 22593124
[TBL] [Abstract][Full Text] [Related]
57. FDG uptake heterogeneity evaluated by fractal analysis improves the differential diagnosis of pulmonary nodules.
Miwa K; Inubushi M; Wagatsuma K; Nagao M; Murata T; Koyama M; Koizumi M; Sasaki M
Eur J Radiol; 2014 Apr; 83(4):715-9. PubMed ID: 24418285
[TBL] [Abstract][Full Text] [Related]
58. Accuracy of fluorodeoxyglucose-positron emission tomography for diagnosis of single bone metastasis: comparison with bone scintigraphy.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
J Comput Assist Tomogr; 2007; 31(5):812-9. PubMed ID: 17895798
[TBL] [Abstract][Full Text] [Related]
59. The role of dynamic, static, and delayed total-body PET imaging in the detection and differential diagnosis of oncological lesions.
Wu Y; Fu F; Meng N; Wang Z; Li X; Bai Y; Zhou Y; Liang D; Zheng H; Yang Y; Wang M; Sun T
Cancer Imaging; 2024 Jan; 24(1):2. PubMed ID: 38167538
[TBL] [Abstract][Full Text] [Related]
60. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
